Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer

BACKGROUND: Lapatinib plus capecitabine is an effective treatment option for trastuzumab-refractory HER2-positive metastatic breast cancer. We have investigated the correlation between quantitative measures of HER2, p95HER2, and HER3 and treatment outcomes using lapatinib and capecitabine. METHODS:...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Han, Sae-Won, Cha, Yongjun, Paquet, Agnes, Huang, Weidong, Weidler, Jodi, Lie, Yolanda, Sherwood, Thomas, Bates, Michael, Haddad, Mojgan, Park, In Hae, Oh, Do-Youn, Lee, Keun Seok, Im, Seock-Ah, Bang, Yung-Jue, Ro, Jungsil, Kim, Tae-You
Format: Artigo
Idioma:Inglês
Publicat: Public Library of Science 2012
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3407213/
https://ncbi.nlm.nih.gov/pubmed/22848366
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0039943
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars